341 results on '"McNally, Orla"'
Search Results
2. Targeting homologous recombination deficiency in uterine leiomyosarcoma
3. Interferon-ε is a tumour suppressor and restricts ovarian cancer
4. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer
5. Pelvic floor muscle training delivered via telehealth to treat urinary and/or faecal incontinence after gynaecological cancer surgery: a single cohort feasibility study
6. Incorporating laparoscopic interval cytoreductive surgery for advanced ovarian cancer-lessons learnt
7. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
8. Natural history of pelvic floor disorders before and after hysterectomy for gynaecological cancer.
9. Abstract B019: Assessing Circulating TumOur DNA as a prognostic biomarker in endometrial cancer (The CODEC Study)
10. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial
11. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
12. Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy
13. Contraceptive strategies for reducing the risk of reproductive cancers.
14. Low‐risk gestational trophoblastic neoplasia – 20 years experience of a state registry.
15. Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care
16. Therapeutic options for mucinous ovarian carcinoma
17. Are endometrial cancer clinical practice management guidelines sufficiently consumer centric?
18. Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer—Quality of Life Evaluation Research) Prospective, International, Multicentre Study
19. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer
20. Pelvic Exenteration for Anal and Urogenital Squamous Cell Carcinoma: Experience and Outcomes from an Exenteration Unit Over 12 Years
21. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
22. Pathological process has a crucial role in sentinel node biopsy for vulvar cancer
23. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer
24. Low‐risk gestational trophoblastic neoplasia – 20 years experience of a state registry
25. EP285/#976 Borderline ovarian tumour audit at an Australian tertiary centre
26. EP016/#819 Organoids as pre-clinical models to assess the efficacy of heated intraperitoneal chemotherapy in mucinous ovarian cancer
27. EP362/#696 New patient-derived models and therapy screening in mucinous ovarian carcinoma
28. EP073/#565 Survival and patterns of failure in small cell neuroendocrine carcinoma of cervix treated with definitive chemoradiotherapy
29. Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
30. Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
31. #824 The correlation between macroscopic surgical assessment, histological and molecular subtypes of high-grade serous cancer of the female genital tract, ovarian, tubal and peritoneal origin- the FOoTPrint study
32. Glucagonoma Masquerading as a Mucinous Cancer of the Ovary: Lessons from Cell Biology
33. The diagnostic accuracy of OCT angiography in naive and treated neovascular age-related macular degeneration: a review
34. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics
35. Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer
36. Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer—Quality of Life Evaluation Research) Prospective, International, Multicentre Study.
37. Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care
38. Supplementary Tables from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
39. Table S4 from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
40. Supplementary Data from Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
41. Data from LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin
42. Supplementary Figures 1-10 from LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin
43. Supplementary Methods from LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin
44. Supplementary Tables 1-6 from LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin
45. Perioperative outcomes of cytoreductive surgery for tumours of colorectal or appendiceal origin with ovarian involvement
46. Shifting incidence and survival of epithelial ovarian cancer (1995-2014):A SurvMark-2 study
47. The molecular origin and taxonomy of mucinous ovarian carcinoma
48. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
49. Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection
50. Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark‐2 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.